Summary
Wearable Device is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Wearable Device to ME/CFS: 1 is currently recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 100500 participants. Registered activity dates to 2023. The literature layer holds 6 publications for this pair: 6 PubMed search records. Publication years run from 2024 to 2026. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 191 candidate agents are logged for ME/CFS, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 14.0 (trials 3.0, literature 6.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 1 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 6 (6 PubMed search records) |
| Agent type | Behavioural (Behavioral / Protocol / Exercise, Medical Device) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not recorded |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05741112 | The Long COVID-19 Wearable Device Study Scripps Translational Science Institute · 2023 | recruiting | Not applicable | 100,500 |
Published literature
- PubMed record (biomarker-intervention search) Rethinking Lactate in Cardiac Surgery and Intensive Care.Journal of cardiothoracic and vascular anesthesia · 2026 · PMID 41963151
- PubMed record (biomarker-intervention search) Continuous lactate monitoring for real-time fatigue assessment in baseball pitchers.Biosensors & bioelectronics · 2026 · PMID 41833085
- PubMed record (biomarker-intervention search) The Effect of Muscle-Damaging Exercise in the Heat on Sleep.Sports health · 2026 · PMID 41749466
- PubMed record (biomarker-intervention search) A daily-durable wearable sweat biosensing device with robust reticular conductive biogel interface.Biosensors & bioelectronics · 2026 · PMID 41442922
- PubMed record (biomarker-intervention search) Multimodal Wearable Platform with Simultaneous Electrochemical and Biophotonic Sensing.ACS sensors · 2025 · PMID 40673838
- PubMed record (biomarker-intervention search) Detecting Hypoxia Through the Non-Invasive and Simultaneous Monitoring of Sweat Lactate and Tissue Oxygenation.Biosensors · 2024 · PMID 39727849
Mechanism and notes
This is a behavioural, rehabilitation or protocol-based intervention rather than a molecule, so no pharmacological mechanism is recorded.
Clinical notes: Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Wearable Device approved for ME/CFS?
Wearable Device is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Wearable Device in clinical trials for ME/CFS?
ClinicalTrials.gov lists 1 registered trial linking Wearable Device to ME/CFS: 1 is currently recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 100500 participants. Registered activity dates to 2023.
What does the evidence show for Wearable Device in ME/CFS?
Trials of Wearable Device in ME/CFS are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.